{"schema_version":"secwatch.filing_event.v1","accession":"0000014272-22-000112","form_type":"8-K","ticker":"BMY","cik":"0000014272","company_name":"BRISTOL MYERS SQUIBB CO","filed_at":"2022-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.646587+00:00","generated_at":"2026-06-26T02:33:04.778361+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bristol-Myers Q1 revenue $11.6B (+5%); Non-GAAP EPS $1.96 (+13%)","bullets":["Revenue $11.648B, +5% YoY (7% ex FX); U.S. revenue $7.7B (+10%).","GAAP EPS $0.59 (down 34%); Non-GAAP EPS $1.96 (up 13%); net $(0.10) Acquired IPRD impact.","In-line products +8% (Eliquis $3.2B +11%, Opdivo $1.9B +12%).","Revlimid $2.8B (-5%) and Abraxane $214M (-32%) as LOE pressures continue.","FDA approved Opdualag (melanoma) and Camzyos (cardiomyopathy) in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0000014272-22-000112","json":"https://secwatch.observer/filing/0000014272-22-000112.json","markdown":"https://secwatch.observer/filing/0000014272-22-000112.md","text":"https://secwatch.observer/filing/0000014272-22-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/14272/000001427222000112/0000014272-22-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14272/000001427222000112/bmy-20220429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T02:33:04.778361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}